Coronavirus company news summary – UK Government supports Oxford and Imperial’s vaccine – BAT’s vaccine is ready for clinical trials

Allie Nawrat 18 May 2020 (Last Updated May 18th, 2020 08:52)

18 May 2020 

The Canadian Center for Vaccinology (CCfV) at Dalhousie University has received approval from Health Canada to conduct the country's first clinical trials of a potential Covid-19 vaccine, which has been developed by Chinese company CanSino Biologics. The trials are expected to be commenced in the coming two weeks following ethics board approval.

The UK Government will provide £84m in funding and manufacturing support for the University of Oxford and Imperial College London researchers working on Covid-19 vaccine programme. Also, Oxford University signed global licensing deal with AstraZeneca, which agreed to produce up to 30 million vaccine doses by September.

Sorrento Therapeutics has reported that its Covid-19 antibody candidate, STI-1499, was able to completely block the virus infection during in-vitro preclinical studies. The company intends to develop an antibody cocktail that would protect from Covid-19.

Cigarette company British American Tobacco (BAT) is ready to study in human clinical trials of its Covid-19 vaccine candidate made using proteins from tobacco leaves, according to Reuters. The vaccine candidate is said to have shown positive immune response in pre-clinical studies. On 15 May, the company filed a pre-investigative new drug application with the US Food and Drug Administration (FDA), which acknowledged the submission.